RAG
RXRX icon

RIA Advisory Group’s Recursion Pharmaceuticals RXRX Stock Holding History

RIA Advisory Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$210K Buy
+21,098
New +$235K 0.09% 130

Other funds holding RXRX

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RIA Advisory Group's RXRX Position: Q1 2024 in Review

RIA Advisory Group opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2024: 21,098 shares worth $210K. The stake represents 0.09% of the portfolio and ranks #130 among its holdings.

249 funds tracked by Wall St. Rank hold RXRX as of Q1 2024.

  • RIA Advisory Group held 21,098 shares of Recursion Pharmaceuticals worth $210K as of Q1 2024.
  • Recursion Pharmaceuticals was a new RIA Advisory Group position in Q1 2024.
  • Recursion Pharmaceuticals made up 0.09% of RIA Advisory Group's portfolio in Q1 2024, its #130 holding.
  • 249 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2024.

Based on RIA Advisory Group's 13F filing for Q1 2024, filed 3 May 2024.